tiprankstipranks
Inozyme announces ‘positive’ results from Phase 1/2 trials of INZ-701
PremiumThe FlyInozyme announces ‘positive’ results from Phase 1/2 trials of INZ-701
15d ago
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
PremiumPress Releases
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
15d ago
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PremiumPress Releases
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18d ago
Inozyme reports 2023 EPS ($1.37), consensus ($1.34)
PremiumThe FlyInozyme reports 2023 EPS ($1.37), consensus ($1.34)
1M ago
Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference
PremiumPress Releases
Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference
2M ago
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PremiumPress Releases
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3M ago
Inozyme files $300M mixed securities shelf
PremiumThe FlyInozyme files $300M mixed securities shelf
6M ago
Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
PremiumPress Releases
Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
6M ago
Inozyme reports Q3 EPS (29c), consensus (32c)
PremiumThe Fly
Inozyme reports Q3 EPS (29c), consensus (32c)
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100